RxDoctor Payments Data

Jennie Gohman, NP

Gerontology · Winston, ORNPI 1417614611

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.9% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 32.2% of the total.

$524in general payments, 2019–2025

Across 24 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$169
  • Otsuka America Pharmaceutical, Inc.$82
  • Novo Nordisk$49
  • Indivior Inc.$45
  • AstraZeneca$33
  • Lilly USA, LLC$32
  • plus $115 from 5 others

What the payments were for

  • Food & beverage$50897%
  • Education$163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$524 in reported general payments places this provider in the 65th percentile of 53 gerontology providers in Oregon.

See all gerontology providers in Oregon

Medicare billing

Part B allowed, 2024
$245
Medicare patients
17
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$23,902
OzempicSemaglutide19$15,434
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,833
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$7,263
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl42$5,948
Insulin Lispro Kwikpen U-100Insulin Lispro17$2,573
Albuterol Sulfate HfaAlbuterol Sulfate65$2,117
Levothyroxine Sodium174$1,777
Atorvastatin Calcium171$1,463
DottiEstradiol21$1,438
Buprenorphine Hcl15$1,290
Potassium Chloride77$1,249
Gabapentin86$1,142
Ventolin HfaAlbuterol Sulfate18$993
Lisinopril169$872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$49$15,43419 claims
GSKTrelegy Ellipta$30$14,83320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 53 gerontology providers in Oregon.

Other gerontology in Winston

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →